apoptosis inducer
CAS：18642-23-4
分子式：C20H16O5
分子量：336.3
纯度：98%
存储：Store at -20°C

Background:

Psoralidin is a dual inhibitor of COX-2 and 5-LOX. Psoralidin, a coumestan derivative isolated from seed of Psoralea corylifolia, has been widely used in traditional medicine for bleeding, pollakiuria, enuresis, vitiligo, and psoriasis. Psoralidin shows a variety of biological activities such as anti-cancer, anti-bacterial, anti-oxidant, anti-depressant activities and regulation of insulin signaling [1].

Psoralidin (100 μM) inhibited COX-2 in IR-irradiated normal lung fibroblasts in HFL-1 and MRC-5 cells [1]. Psoralidin significantly inhibited IR-induced NF-κB-luciferase activity. Psoralidin inhibited the IR-induced COX-2 expression and PGE2 production through regulation of PI3K/Akt and NF-κB pathway. Also, psoralidin blocked IR-induced LTB4 production through direct interaction with 5-lipoxygenase activating protein (FLAP) in 5-LOX pathway. Psoralidin significantly attenuated IR-induced fibroblast migration [1]. Psoralidin inhibited LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways [2]. Psoralidin enhanced TRAIL-induced apoptosis in HeLa cells through increased expression of TRAIL-R2 death receptor and depolarization of mitochondrial membrane potential [3].

In male BALB/c strain mice (eight weeks, average weight 22–25 g), psoralidin (5 mg/kg) suppressed IR-induced expression of pro-inflammatory cytokines (TNF-α, TGF-β, IL-6 and IL-1 α/β) and ICAM-1 [1].

参考文献:
[1] Yang H J, Youn H S, Seong K M, et al.  Psoralidin, a dual inhibitor of COX-2 and 5-LOX, regulates ionizing radiation (IR)-induced pulmonary inflammation[J]. Biochemical pharmacology, 2011, 82(5): 524-534.
[2] Chiou W F, Don M J, Liao J F, et al.  Psoralidin inhibits LPS-induced iNOS expression via repressing Syk-mediated activation of PI3K-IKK-IκB signaling pathways[J]. European journal of pharmacology, 2011, 650(1): 102-109.
[3] Bronikowska J, Szliszka E, Jaworska D, et al.  The coumarin psoralidin enhances anticancer effect of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)[J]. Molecules, 2012, 17(6): 6449-6464.